骨髓Tfr2缺失提高激活素受体配体陷阱RAP-536对β-地中海贫血小鼠的治疗效果
在Hbbth3/+β-地中海贫血小鼠中,造血细胞Tfr2缺失与RAP-536(Luspatercept鼠源类似物)单用均改善无效造血和贫血,两法联用呈相加效应;RAP-536在有无Tfr2缺失时疗效相当,提示其促红系分化不依赖TFR2与EPO刺激,而Tfr2缺失还可减轻铁过载及相关并发症。
要点
- 造血细胞Tfr2缺失与RAP-536单用均显著改善Hbbth3/+小鼠的无效造血和贫血。
- 两法联用对改善无效造血和贫血呈相加效应。
- RAP-536在Hbbth3/+与Tfr2BMKO/Hbbth3/+小鼠中疗效相当,提示其促红系分化不依赖TFR2和EPO刺激。
核心结论
- 结果进一步阐明Luspatercept的作用机制,并提示抑制造血细胞TFR2的策略可能提高激活素受体配体陷阱的疗效。
研究设计与样本
- 研究使用Hbbth3/+地中海贫血小鼠,比较有无造血细胞Tfr2缺失(Tfr2BMKO/Hbbth3/+)时给予RAP-536(Luspatercept鼠源类似物)治疗的效果。
主要发现
- 造血细胞Tfr2缺失和RAP-536均显著改善无效造血和贫血,联合方案呈相加效应。
- RAP-536在Hbbth3/+与Tfr2BMKO/Hbbth3/+动物中疗效相当。
- Tfr2缺失可减轻铁过载及相关并发症,RAP-536无此作用。
临床怎么用
- 作者提出,旨在抑制造血细胞TFR2的策略可能提高激活素受体配体陷阱的治疗疗效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
β-thalassemia is a disorder characterized by anemia, ineffective erythropoiesis (IE), and iron overload, whose treatment still requires improvement. The activin receptor-ligand trap Luspatercept, a novel therapeutic option for β-thalassemia, stimulates erythroid differentiation inhibiting the transforming growth factor β pathway. However, its exact mechanism of action and the possible connection with erythropoietin (Epo), the erythropoiesis governing cytokine, remain to be clarified. Moreover, Luspatercept does not correct all the features of the disease, calling for the identification of strategies that enhance its efficacy. Transferrin receptor 2 (TFR2) regulates systemic iron homeostasis in the liver and modulates the response to Epo of erythroid cells, thus balancing red blood cells production with iron availability. Stimulating Epo signaling, hematopoietic Tfr2 deletion ameliorates anemia and IE in Hbbth3/+ thalassemic mice. To investigate whether hematopoietic Tfr2 inactivation improves the efficacy of Luspatercept, we treated Hbbth3/+ mice with or without hematopoietic Tfr2 (Tfr2BMKO/Hbbth3/+) with RAP-536, the murine analog of Luspatercept. As expected, both hematopoietic Tfr2 deletion and RAP-536 significantly ameliorate IE and anemia, and the combined approach has an additive effect. Since RAP-536 has comparable efficacy in both Hbbth3/+ and Tfr2BMKO/Hbbth3/+ animals, we propose that the drug promotes erythroid differentiation independently of TFR2 and EPO stimulation. Notably, the lack of Tfr2, but not RAP-536, can also attenuate iron-overload and related complications. Overall, our results shed further light on the mechanism of action of Luspatercept and suggest that strategies aimed at inhibiting hematopoietic TFR2 might improve the therapeutic efficacy of activin receptor-ligand traps.
引用
- Tanzi E, Di Modica SM, Bordini J, et al. Bone marrow Tfr2 deletion improves the therapeutic efficacy of the activin-receptor ligand trap RAP-536 in β-thalassemic mice. Am J Hematol. 2024. PMID: 38629683. doi:10.1002/ajh.27336
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。